Search the web
Welcome, Guest
[Sign Out, My Account]

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
PCRX > SEC Filings for PCRX > Form 8-K on 14-Jun-2013All Recent SEC Filings

Show all filings for PACIRA PHARMACEUTICALS, INC. | Request a Trial to NEW EDGAR Online Pro



Change in Directors or Principal Officers, Submission of Matters to

Item 5.02. Departure of Directors or Certain Officers;
Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On June 12, 2013, the Board of Directors of Pacira Pharmaceuticals, Inc. (the "Company") appointed Mark A. Kronenfeld, M.D. to serve as a Class I director until the 2015 Annual Meeting of Stockholders, subject to the election and qualification of his successor or his earlier death, resignation or removal.

Dr. Kronenfeld has been the Vice Chairman of Anesthesiology at Maimonides Medical Center, a large tertiary care academic medical center in New York City, since March 2009, and has served as Medical Director of Perioperative Services for Maimonides Medical Center since January 2011. Dr. Kronenfeld is a managing partner of Anesthesia Associates of Boro Park, a private medical practice, and a managing partner of Strategic Medical Management Partners. In 2001, Dr. Kronenfeld founded Ridgemark Capital Management ("Ridgemark"), a healthcare-focused hedge fund that invested in public and private healthcare and biomedical companies. He served as the Managing Partner and Portfolio Manager of Ridgemark from April 2001 to December 2008. Dr. Kronenfeld has founded and/or managed various consulting and investment companies focused on healthcare and medical technologies and has served on and chaired multiple leadership committees for various hospitals and medical centers. Previously, Dr. Kronenfeld taught and practiced adult and pediatric cardiac anesthesia at NYU and was Chief of Cardiac Anesthesiology at Hackensack University Medical Center and President of GMS Anesthesia Associates, a private medical practice. Dr. Kronenfeld received his M.D. degree and completed his residency in Anesthesiology at the University of California, San Diego School of Medicine, and completed a fellowship in Cardiothoracic Anesthesiology at New York University Medical Center. While an Assistant Professor and Attending Cardiac Anesthesiologist at NYU, Dr. Kronenfeld received and completed a Kellogg-sponsored Fellowship in Heath Care Management for Future Leaders in Health Care at NYU's Graduate School of Management.

The committees of the Board to which Dr. Kronenfeld will be appointed have not been determined as of the date of this filing. As compensation for his service on the Board, Dr. Kronenfeld will receive the Company's standard compensation for non-employee directors as described in the Company's definitive proxy statement filed with the SEC on April 25, 2013. There are no understandings or arrangements between Dr. Kronenfeld and any other person pursuant to which he was selected as a director.

Item 5.07. Submission of Matters to a Vote of Security Holders.

The 2013 Annual Meeting of Stockholders of the Company was held on June 11, 2013 at the Company's corporate headquarters in Parsippany, New Jersey, at which the following matters were submitted to a vote of the stockholders:

Proposal No. 1 - Election of three Class II Directors to hold office until the 2016 Annual Meeting, and until their respective successors have been duly elected and qualified.

                                           Broker Non-
Nominee:              For       Withheld      Votes
Paul Hastings      22,606,162   142,193     5,049,525
John Longenecker   22,608,812   139,543     5,049,525
Andreas Wicki      22,641,417   106,938     5,049,525

Proposal No. 2 - Ratification of the Appointment of CohnReznick LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2013.

For Against Abstain
27,470,773 317,641 9,466

Proposal No. 3 - Advisory vote to approve the compensation of the Company's named executive officers.

For Against Abstain Broker Non-Votes 17,502,752 5,203,868 41,735 5,049,525

Proposal No. 4 - Advisory vote to approve the frequency of future advisory votes to approve the compensation of our named executive officers.

One Year Two Years Three Years Abstain Broker Non-Votes 20,677,536 1,205,083 863,549 2,187 5,049,525

  Add PCRX to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for PCRX - All Recent SEC Filings
Sign Up for a Free Trial to the NEW EDGAR Online Pro
Detailed SEC, Financial, Ownership and Offering Data on over 12,000 U.S. Public Companies.
Actionable and easy-to-use with searching, alerting, downloading and more.
Request a Trial      Sign Up Now

Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.